Univest
Univest
  • Markets
  • Anthem Biosciences Analyst Review 2027: Q2 Profit Beat Keeps Brokers at ₹1,000 to ₹1,050

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Anthem Biosciences Analyst Review 2027: Q2 Profit Beat Keeps Brokers at ₹1,000 to ₹1,050

    Anthem Biosciences grew Q2 FY27 profit about 22% to ₹211 crore on an EBITDA margin above 50%, beating PL Capital’s estimate. PL Capital holds a ₹1,050 target and JPMorgan ₹1,000. We review brokerage views, results, the CRDMO model, valuation and risks.

    read more